Polyrizon is an Israeli development-stage hydrogel company that has finally moved its allergy-blocker nasal spray from the lab toward first-in-human testing, and the equity now turns on whether that clinic work stays the main use of cash. Management completed contracts with all five United States trial sites for NASARIX in early September. The same week the company closed a $4 million registered-direct round. The coincidence is the story: the first human study is ready, and the balance sheet is still being topped up in small slices.
The deeper tension is not the trial design. It is what else the cash might buy. The board has already signed non-binding memoranda to take a majority stake in a private-aviation operator and a minority stake in an electric vertical-takeoff drone developer. Combined consideration on those letters sits near $12 million. Year-end liquid resources were about $18 million before later equity sales. Spending a large slice of that pile on aircraft and drones would leave the allergy study competing with a conglomerate experiment. The market is being asked to underwrite a first human readout and an aviation sidecar at the same time.
The latest audited year still showed no product revenue and a widened operating loss after the listing completed near the end of the prior year. The ordinary share last changed hands near $11. Equity value sits near $26 million. Whether NASARIX enrolls on the allergy calendar, and whether the aviation letters stay letters, is the question the next several seasons actually resolve.